The Technical AnalystExchange: EURONEXT Sector: Healthcare Industry: Biotechnology
Pherecydes Pharma Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.50% €2.00
America/New_York / 23 jun 2023 @ 11:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 15.83 mill |
| EPS: | -0.750 |
| P/E: | -2.67 |
| Earnings Date: | Mar 07, 2023 |
| SharesOutstanding: | 7.92 mill |
| Avg Daily Volume: | 0.0105 mill |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 4/20 | 2/21 | 4/21 | 2/22 | 4/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.67 | sector: PE 17.08 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -2.67 | industry: PE -7.48 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
€ 1.867 - 2.07 ( +/- 5.23%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €2.00 (-0.50% ) |
| Volume | 0.0032 mill |
| Avg. Vol. | 0.0105 mill |
| % of Avg. Vol | 30.02 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALPHE.PA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ALPHE.PA
Pherecydes Pharma SA develops antibacterial treatments based on the use of bacteriophage viruses or phages. It develops a portfolio of therapeutics, such as anti-Staphylococcus aureusphages for the treatment of bone/joint and diabetic foot ulcer infections; anti-Pseudomonas aeruginosa phages for the treatment of complicated urinary tract infections; and anti-Escherichia coli phages for the treatment of respiratory tract infections. The company was founded in 2006 and is based in Romainville, France.